BRAF and central nervous system cancer: BRAFV600E mutation is the second most frequent mutation in pediatric low-grade glioma (LGG) but the alteration has also been reported in a subset of primary and secondary high-grade glioma (HGG).1 The overall survival of HGG BRAFV600E mutation is more favorable than other subgroups including HGG H3.3 G34 R/V but despite standardized treatment strategies including surgery, radiation therapy, and chemotherapy the prognosis is poor.2,3 New treatment approaches are currently being investigated including BRAF inhibitors (BRAFi) with or without MEKi for LGG and HGG with BRAFV600E mutation.